Literature DB >> 2788509

Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies.

W H West1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2788509     DOI： 10.1016/0305-7372(89)90027-3

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  8 in total

1.  Persistent augmentation of natural-killer- and T-cell-mediated cytotoxicity in peripheral blood mononuclear cells pulsed in vitro with high-dose recombinant interleukin-2 prior to culturing with a low maintenance dose.

Authors:  P A Palmer; J G Scharenberg; B M von Blomberg; A G Stam; C J Meijer; G J Roest; C R Franks; R J Scheper
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

2.  Spontaneous regression of metastatic renal cell carcinoma following palliative irradiation of the primary tumour.

Authors:  M P MacManus; R J Harte; S Stranex
Journal:  Ir J Med Sci       Date:  1994-10       Impact factor: 1.568

Review 3.  Designing and Immunomodulating Multiresponsive Nanomaterial for Cancer Theranostics.

Authors:  Amreen Khan; Faith Dias; Suditi Neekhra; Barkha Singh; Rohit Srivastava
Journal:  Front Chem       Date:  2021-01-29       Impact factor: 5.221

4.  Cytochalasin B-Induced Membrane Vesicles from Human Mesenchymal Stem Cells Overexpressing IL2 Are Able to Stimulate CD8+ T-Killers to Kill Human Triple Negative Breast Cancer Cells.

Authors:  Daria S Chulpanova; Zarema E Gilazieva; Sevindzh K Kletukhina; Aleksandr M Aimaletdinov; Ekaterina E Garanina; Victoria James; Albert A Rizvanov; Valeriya V Solovyeva
Journal:  Biology (Basel)       Date:  2021-02-10

5.  Key biomarkers within the colorectal cancer related inflammatory microenvironment.

Authors:  Valentin Calu; Adriana Ionescu; Loredana Stanca; Ovidiu Ionut Geicu; Florin Iordache; Aurelia Magdalena Pisoschi; Andreea Iren Serban; Liviu Bilteanu
Journal:  Sci Rep       Date:  2021-04-12       Impact factor: 4.379

6.  A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.

Authors:  P Lissoni; S Barni; G Tancini; A Ardizzoia; G Ricci; R Aldeghi; F Brivio; E Tisi; F Rovelli; R Rescaldani
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

7.  Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma.

Authors:  R A Janssen; D T Sleijfer; A A Heijn; N H Mulder; T H The; L de Leij
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

Review 8.  Harnessing the immune system in the battle against breast cancer.

Authors:  Elizabeth S Nakasone; Sara A Hurvitz; Kelly E McCann
Journal:  Drugs Context       Date:  2018-02-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.